bosentan
Orphan DrugFDA Approved
Description
Bosentan is an endothelin receptor antagonist used to treat pulmonary arterial hypertension. It blocks endothelin receptors, preventing vasoconstriction and reducing pulmonary vascular resistance. Regular liver function monitoring is required during treatment.
Indications & Therapeutic Use
pulmonary arterial hypertension, WHO Group 1 pulmonary hypertension
Linked Diseases:
pulmonary hypertension
D006976
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
bosentan
| Generic Name | bosentan |
| Brands | 1 brand available |
| Active Ingredient | bosentan |
| Drug Class | pulmonary arterial hypertension |
| Manufacturer | Actelion Pharmaceuticals |
| Dosage Forms | oral tablet 62.5mg, 125mg; dispersible tablet 32mg |
| Medical Code | C02KX01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 10 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00091559 |
| Countries | 9 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations10 Validated Nodes